{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:02:29Z","timestamp":1783648949594,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1053\/j.ajkd.2022.02.012","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:43:17Z","timestamp":1650501797000},"page":"158-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors"],"prefix":"10.1053","volume":"80","author":[{"given":"Biff F.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11 Suppl","key":"10.1053\/j.ajkd.2022.02.012_bib1","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1053\/j.ajkd.2022.02.012_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2022.02.012_bib3","first-page":"R989","article-title":"Renal potassium transport: morphological and functional adaptations","volume":"257","author":"Stanton","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ajkd.2022.02.012_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1172\/JCI112783","article-title":"Independent effects of aldosterone and potassium on induction of potassium adaptation in rat kidney","volume":"79","author":"Stanton","year":"1987","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.ajkd.2022.02.012_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1056\/NEJMra1503102","article-title":"Electrolyte and acid-base disorders in patients with diabetes mellitus","volume":"373","author":"Palmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2022.02.012_bib6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI109615","article-title":"Attenuation of angiotensin II and III induced aldosterone release by prostaglandin synthesis inhibitors","volume":"64","author":"Campbell","year":"1979","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.ajkd.2022.02.012_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2022.02.012_bib8","first-page":"516","article-title":"Renal complications associated with use of non-steroidal antiinflammatory agents","volume":"43","author":"Palmer","year":"1995","journal-title":"J\u00a0Invest Med"},{"key":"10.1053\/j.ajkd.2022.02.012_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ki.1991.321","article-title":"Adrenergic modulation of extrarenal potassium disposal in men with end-stage renal disease","volume":"40","author":"Allon","year":"1991","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2022.02.012_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.xkme.2020.04.007","article-title":"Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet","volume":"2","author":"Clegg","year":"2020","journal-title":"Kidney Med"},{"issue":"2","key":"10.1053\/j.ajkd.2022.02.012_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"10208","key":"10.1053\/j.ajkd.2022.02.012_bib12","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"31","key":"10.1053\/j.ajkd.2022.02.012_bib13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"48","key":"10.1053\/j.ajkd.2022.02.012_bib14","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1053\/j.ajkd.2022.02.012_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"}],"updated-by":[{"DOI":"10.1053\/j.ajkd.2022.09.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000}}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622005224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622005224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T22:00:45Z","timestamp":1666562445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622005224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0272638622005224"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.02.012","relation":{"erratum":[{"id-type":"doi","id":"10.1053\/j.ajkd.2022.09.001","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}